Lesson 4 - Stimulant Medication in ADHD

1. Introduction

Why This Topic Matters

Stimulant medication is one of the most important treatment options available for ADHD and prescribing it safely requires considerably more than knowing which medication to start.

For many children, young people and adults with ADHD, stimulant medication can produce meaningful improvements in core symptoms including inattention, hyperactivity and impulsivity. These improvements may translate into better functioning in education, employment, relationships and everyday life.

However, treatment is highly individual.

Two people with apparently similar ADHD presentations may respond very differently to the same medication. One may experience substantial benefit at a relatively low dose while another may require careful dose optimisation. Some experience adverse effects before meaningful benefit emerges. Others respond poorly to one stimulant class but very well to another.

The clinician therefore needs to understand not simply:

"Which medications treat ADHD?"

but:

"How do I select, initiate, titrate, monitor and optimise stimulant medication safely for this individual?"

This lesson focuses on developing that practical clinical understanding.

Stimulants Are Not a Single Treatment

The term stimulant medication can create the impression that we are discussing one relatively uniform treatment.

In practice, several important distinctions need to be understood.

The two principal stimulant groups used in ADHD treatment are:

Methylphenidate-based medications

and

Amphetamine-based medications, including Lisdexamfetamine and Dexamfetamine.

Within these groups there are immediate-release and modified-release preparations with different pharmacokinetic profiles.

This matters clinically.

A patient may report:

"Methylphenidate didn't work."

Before accepting that conclusion, we need to know:

• which preparation was used

• what dose was reached

• how long it was taken

• whether it was taken consistently

• what time it was taken

• how long any benefit lasted

• what adverse effects occurred

• whether there was adequate titration

• what functional outcomes were being assessed

Similarly, modified-release Methylphenidate preparations should not automatically be viewed as interchangeable simply because they contain the same active drug. Their release characteristics can differ and this may influence onset, duration and the individual's experience of treatment.

Understanding formulations is therefore an important part of competent stimulant prescribing.

Treatment Is About Optimisation, Not Simply Starting Medication

Starting medication is relatively straightforward.

Optimising it is more difficult.

The purpose of titration is to identify a dose that produces the best achievable balance between:

improvement in symptoms and functioning

and

adverse effects.

The objective is not automatically to reach the highest permitted dose.

Nor should treatment necessarily stop because the first dose produces little improvement.

Initial doses are deliberately cautious. Depending on the medicine and individual circumstances, a starting dose may provide limited therapeutic benefit while still allowing the clinician to assess tolerability before increasing treatment.

During titration, clinicians should repeatedly ask:

Is it helping?

How much is it helping?

When does the benefit begin?

How long does it last?

What happens when it wears off?

Are there adverse effects?

Has functioning actually improved?

This is medication optimisation rather than simple dose escalation.

Measure Function, Not Just Symptoms

A patient saying:

"My concentration is better"

is useful information.

But it is not enough.

We also want to know whether treatment has changed meaningful areas of functioning.

For a child, this might include:

• remaining engaged with classroom activities

• completing work

• following instructions

• reducing disruptive impulsive behaviour

• managing routines more effectively

• improving relationships with peers or family

For an adult, it might include:

• completing administrative work

• managing deadlines

• following conversations

• reducing careless mistakes

• improving organisation

• reducing impulsive decisions

• functioning more effectively at home or work

Medication should ultimately be judged by whether it produces clinically meaningful benefit in the person's life.

Monitoring Is Part of Treatment

Stimulants require appropriate physical and psychiatric monitoring.

Before treatment begins, clinicians need to consider factors such as:

• cardiovascular history

• current medication

• physical health

• height and weight where appropriate

• pulse and blood pressure

• psychiatric comorbidity

• substance misuse and diversion risk

• potential contraindications

• baseline symptoms and functional impairment

Monitoring continues during titration and maintenance.

Depending on the individual and stage of treatment, this may include:

• pulse

• blood pressure

• weight

• height and growth in children and young people

• appetite

• sleep

• mood

• anxiety

• behavioural change

• cardiovascular symptoms

• emergence or worsening of tics

• effectiveness

• duration of benefit

• adherence

• misuse or diversion concerns

Monitoring should not become a mechanical checklist.

The purpose is to determine whether treatment remains effective, safe and appropriate.

Adverse Effects Need Clinical Interpretation

Common adverse effects can include reduced appetite, sleep difficulties, headache and gastrointestinal symptoms. Changes in pulse or blood pressure may also occur.

The presence of an adverse effect does not automatically mean that medication must be stopped.

Equally, a medication should not simply be continued because an adverse effect appears on a list of recognised effects.

Clinical judgement is required.

Consider:

• severity

• timing

• persistence

• dose relationship

• functional impact

• physical risk

• alternative explanations

• whether adjustment could resolve the problem

For example, mild appetite reduction at lunchtime requires a different response from substantial weight loss.

A slight delay in sleep onset requires a different response from severe persistent insomnia.

Benign awareness of a faster heartbeat requires a different assessment from chest pain, syncope or clinically significant tachycardia.

The clinician must interpret symptoms within the wider clinical picture.

Medication Choice Is Individualised

There is no universally "best" stimulant for every person with ADHD.

Medication selection may be influenced by:

• age

• symptom profile

• required duration of effect

• previous medication response

• adverse effects

• ability to swallow particular formulations

• daily routine

• school or employment demands

• adherence

• comorbidities

• risk of misuse or diversion

• patient and family preference

For example, a young person may require symptom coverage throughout the school day without medication administration at school.

An adult may need reliable coverage across a long working day.

Another patient may value greater flexibility over the duration of effect.

These considerations influence the formulation selected as well as the active medication.

Medication Does Not Replace Formulation

A patient can respond extremely well to stimulant medication and still experience difficulties.

Medication may improve attention and impulse control but it does not automatically:

• create an organisational system

• repair disrupted relationships

• teach study skills

• resolve accumulated academic difficulties

• correct years of low self-esteem

• improve an unsuitable working environment

• treat every co-occurring psychiatric condition

Medication should therefore remain part of the broader formulation developed throughout this course.

The appropriate question is not:

"Does this patient need medication or non-pharmacological treatment?"

For many patients, the answer may be:

both.

Controlled Drugs and Prescribing Responsibility

Stimulant prescribing also carries responsibilities beyond ordinary medication selection.

Many stimulant medications used for ADHD are controlled drugs in the UK. Clinicians therefore need to understand the relevant prescribing requirements and maintain appropriate standards around:

• prescription writing

• quantities supplied

• safe storage

• lost prescriptions

• early requests

• misuse

• diversion

• travel

• continuity of prescribing

These issues are not administrative details separate from clinical care.

They form part of safe stimulant prescribing.

Shared Care and Continuity of Treatment

ADHD treatment frequently involves different parts of the healthcare system.

Specialists may initiate and optimise medication before prescribing responsibility is subsequently shared with primary care where appropriate and where an agreed shared-care arrangement is in place.

Clinicians should therefore understand:

• when medication can reasonably be considered optimised

• what monitoring remains necessary

• what information should be communicated to primary care

• what responsibilities remain with specialist services

• when a patient needs specialist review again

Starting medication is only the beginning of the treatment pathway.

How This Lesson Fits Into the Overall Course

The earlier lessons established the foundations required before medication should be considered.

We have covered:

ADHD symptoms

↓

Developmental history

↓

Functional impairment

↓

Collateral information

↓

Screening and structured assessment

↓

Differential diagnosis

↓

Comorbidity

↓

Risk assessment

↓

Diagnostic formulation

↓

Explaining the diagnosis

↓

Psychoeducation

↓

Non-pharmacological management

We now move into pharmacological treatment.

This sequencing is deliberate.

Medication should not be prescribed simply because someone reports poor concentration or has a positive screening questionnaire.

Before prescribing, the clinician should understand:

the diagnosis

the severity of symptoms

the functional impairment

the wider psychiatric and physical formulation

the individual's treatment goals

the potential benefits and risks of treatment

Only then can medication selection and titration be properly individualised.

This lesson will therefore examine the practical principles of stimulant prescribing, including:

• Methylphenidate and amphetamine-based medications

• immediate-release and modified-release preparations

• selecting an appropriate medication and formulation

• baseline assessment

• initiation

• titration

• monitoring response

• assessing functional improvement

• managing common adverse effects

• recognising situations requiring greater caution

• switching medication

• adherence

• misuse and diversion

• controlled-drug considerations

• longer-term monitoring and review

The central principle throughout the lesson is:

Stimulant prescribing is not simply choosing a medication and increasing the dose. It is a structured process of selecting, titrating, monitoring and reviewing treatment to achieve meaningful functional benefit while minimising risk and adverse effects.

2. Learning Outcomes

By the end of this lesson, learners should be able to:

1. Explain the role of stimulant medication in the treatment of ADHD, including the main differences between Methylphenidate and amphetamine-based medications and the place of stimulant treatment within a broader individualised management plan.

2. Select an appropriate stimulant medication and formulation, taking into account age, required duration of symptom control, previous treatment response, comorbidity, adherence, individual circumstances, patient preference and the potential for misuse or diversion.

3. Safely initiate and titrate stimulant medication, including completing an appropriate baseline assessment, using a structured titration process and identifying the dose that provides the best balance between symptom improvement, functional benefit and adverse effects.

4. Monitor the effectiveness and safety of stimulant treatment, including assessment of ADHD symptoms, functional outcomes, appetite, sleep, weight, growth where appropriate, pulse, blood pressure, mental state and other clinically relevant adverse effects.

5. Recognise and manage common problems arising during stimulant treatment, including insufficient duration of effect, limited therapeutic response, appetite suppression, sleep difficulties, cardiovascular symptoms, mood or behavioural changes and situations in which switching medication or seeking further assessment should be considered.

6. Apply the principles of safe longer-term stimulant prescribing, including appropriate review, controlled-drug considerations, assessment of adherence and diversion risk, communication with other healthcare professionals and shared-care arrangements where appropriate.

3. The Lecture

Stimulant Prescribing Is a Process

When doctors first learn about ADHD medication, there is a temptation to think in terms of a simple algorithm:

Diagnose ADHD → prescribe stimulant → increase dose → symptoms improve

Clinical practice is more nuanced.

Good stimulant prescribing involves several distinct decisions:

Is medication indicated?

↓

Is stimulant treatment appropriate for this individual?

↓

Which stimulant should we use?

↓

Which formulation best fits the person's day?

↓

What baseline assessment is required?

↓

How should treatment be titrated?

↓

Is it actually working?

↓

Is the duration of effect appropriate?

↓

Are adverse effects acceptable?

↓

Is this the best achievable balance between benefit and tolerability?

The clinician's role is therefore not simply to prescribe a stimulant.

It is to optimise treatment for an individual patient.

The Two Main Stimulant Families

The two principal stimulant groups used in ADHD treatment are:

Methylphenidate-based medication

and

Amphetamine-based medication

In UK practice, the latter commonly involves Lisdexamfetamine or Dexamfetamine.

Both groups can be highly effective.

However, response is individual.

A patient who responds poorly to an adequate trial of Methylphenidate may respond very well to an amphetamine-based treatment and vice versa.

This is an important concept to explain to patients.

A poor response to one stimulant does not necessarily mean:

"Stimulants don't work for me."

It may mean:

"This particular stimulant, formulation or dose has not produced an adequate balance of benefit and tolerability."

How Do Stimulants Work?

At a practical level, stimulant medications increase catecholaminergic signalling, particularly involving dopamine and noradrenaline.

Methylphenidate primarily inhibits dopamine and noradrenaline reuptake.

Amphetamine-based medications have additional effects on catecholamine release.

For routine clinical practice, however, avoid reducing ADHD to:

"You have a dopamine deficiency and this medication replaces dopamine."

That explanation is overly simplistic.

A more clinically appropriate explanation might be:

"These medicines influence brain signalling systems involved in attention, impulse control and regulation. In people who respond, this can make it easier to regulate attention and behaviour."

The patient does not need an inaccurate neurochemical story in order to understand why treatment may help.

What Are We Trying to Improve?

Before prescribing, define the treatment targets.

For example, a parent might say:

"I want him to concentrate better."

Ask what that would look like.

Perhaps the actual targets are:

• completing more classroom work

• following instructions more consistently

• interrupting less frequently

• remaining seated when appropriate

• completing the morning routine

• reducing impulsive conflict with siblings

For an adult, treatment targets might include:

• completing documentation

• following conversations

• reducing careless errors

• managing deadlines

• improving task completion

• reducing impulsive decision-making

• functioning more consistently at home

This matters because otherwise medication titration becomes vague.

If we do not know what we are trying to change, it becomes difficult to determine whether treatment is working.

Baseline Assessment

Before starting stimulant medication, undertake an appropriate baseline assessment.

The exact assessment should follow current prescribing guidance and the individual's clinical circumstances but the principles are consistent.

Confirm the Clinical Picture

Before prescribing, confirm that:

• ADHD has been appropriately diagnosed

• symptoms are causing clinically meaningful impairment

• the treatment plan has been discussed

• relevant non-pharmacological approaches have been considered

• the patient or family understands the purpose of medication

Do not allow the medication appointment to become a substitute for diagnostic assessment.

Physical Health

Baseline physical assessment should include relevant physical health history and medication history.

Record appropriate baseline measurements including:

• pulse

• blood pressure

• weight

• height where clinically appropriate

For children and young people, growth monitoring is particularly important.

Consider the cardiovascular history carefully.

Ask about clinically relevant symptoms such as:

• exertional syncope

• unexplained fainting

• significant palpitations

• chest pain suggestive of cardiac origin

• unexplained breathlessness

Consider personal and relevant family cardiac history.

Where findings suggest increased cardiovascular risk, further medical or cardiology assessment may be required before treatment.

Do All Patients Need an ECG?

No.

An ECG should not simply be ordered routinely for every patient because stimulant medication is being considered.

The need for further cardiovascular investigation should be determined by the clinical history, examination, concurrent medication and other relevant risk factors.

This is a useful general prescribing principle:

Investigate because there is a clinical indication, not because prescribing has become a ritual.

Mental Health Assessment

Stimulant prescribing also requires an understanding of the wider psychiatric formulation.

Consider:

• anxiety

• depression

• bipolar disorder

• psychotic symptoms

• autism

• tics

• eating difficulties

• substance misuse

• emotional dysregulation

• sleep

• risk

This does not mean that every co-occurring condition prevents stimulant treatment.

It means that the clinician needs to know what is present before treatment begins.

Otherwise, if symptoms change during titration, it may be difficult to determine whether this represents:

• the underlying condition

• a medication effect

• a dose-related effect

• another emerging disorder

Misuse and Diversion

Stimulants are controlled drugs and the potential for misuse and diversion should be considered.

Risk may be particularly relevant where there is:

• current substance misuse

• previous stimulant misuse

• repeated lost prescriptions

• unexplained early medication requests

• pressure for particular formulations

• evidence that medication is being shared or sold

Do not assume that everyone with a history of substance use should automatically be denied ADHD treatment.

Equally, do not ignore diversion risk because ADHD has been clearly diagnosed.

Individualised risk assessment is required.

Choosing the Initial Stimulant

Medication choice should follow current clinical guidance and take account of the person's age and circumstances.

But even within guideline recommendations, there are practical decisions.

Ask:

How long does symptom control need to last?

When are the most important periods of impairment?

Can the patient reliably take medication more than once daily?

Would administration during school or work create difficulties?

Is there concern about misuse or diversion?

Can the patient swallow the proposed formulation?

What previous medication has been tried?

The answer influences both the drug and the formulation.

Immediate-Release and Modified-Release Medication

This distinction is fundamental.

Immediate-Release Preparations

Immediate-release stimulants generally have a shorter duration of action.

Potential advantages include:

• flexibility

• easier adjustment of timing

• usefulness when only a shorter period of coverage is required

• potential use to supplement longer-acting medication in selected circumstances

Potential disadvantages include:

• repeated dosing

• medication administration during school or work

• greater risk of missed doses

• greater potential for misuse or diversion in some circumstances

• fluctuations in symptom control

Modified-Release Preparations

Modified-release preparations are designed to provide longer symptom coverage from a single dose.

Potential advantages include:

• once-daily administration

• improved convenience

• reduced need for medication administration during school or work

• longer symptom coverage

• potentially improved adherence

• reduced opportunities for diversion compared with some immediate-release arrangements

However, the phrase modified release does not mean that every preparation behaves identically.

Methylphenidate Formulations Are Not Necessarily Interchangeable

This is an important practical prescribing point.

Different modified-release Methylphenidate products can have different release profiles.

They may differ in:

• proportion released immediately

• proportion released later

• timing of later release

• duration of clinical effect

• relationship to food

• formulation characteristics

Consequently, switching between preparations may change the patient's experience even when the total milligram dose appears similar.

Do not think only:

Methylphenidate 20mg = Methylphenidate 20mg

Think:

Which formulation?

What release profile?

When is benefit required?

How does this particular patient experience it?

This is why prescribing by brand can be clinically important for modified-release Methylphenidate preparations.

Think About the Patient's Day

A medication should fit the patient's functional requirements.

Consider a child whose main difficulties occur:

• during school

• during homework

• during the evening family routine

A preparation that provides excellent school coverage but wears off before homework may not fully address the treatment goals.

Conversely, a child who only requires school-day coverage may not need medication effects extending late into the evening.

For an adult, ask:

"What time do you start work?"

"When do you need your best concentration?"

"What time do you finish?"

"Do you have responsibilities in the evening?"

Medication duration should be considered in relation to the person's actual life, not an abstract estimate from a pharmacology table.

Starting Low Does Not Mean Expecting Full Benefit

Patients should understand what the starting dose is trying to achieve.

A useful explanation is:

"We usually begin cautiously so that we can assess how you tolerate the medication. The first dose may not provide the full benefit we are looking for. We then adjust treatment according to benefit and adverse effects."

This prevents two common misunderstandings.

The first is:

"The first dose did very little, therefore the medication doesn't work."

The second is:

"The first dose helped a little, therefore we should immediately increase it as much as possible."

Neither is appropriate.

Titration is a process.

The Principle of Titration

The aim is to identify the dose that produces the best balance between:

therapeutic benefit

and

adverse effects.

Think of titration as searching for an optimal therapeutic window.

Too little medication may produce:

• minimal symptom improvement

• inadequate duration

• persistent impairment

An appropriate dose may produce:

• meaningful symptom reduction

• improved functioning

• acceptable tolerability

Too much medication may produce:

• increasing adverse effects

• emotional flattening

• excessive activation or restlessness

• appetite problems

• sleep disturbance

• cardiovascular effects

• deterioration in overall functioning

The objective is not:

maximum dose

It is:

optimal dose.

What Should You Ask During Titration?

Do not simply ask:

"How are you getting on with the medication?"

That often produces:

"Fine."

Instead structure the review.

Benefit

Ask:

• What has improved?

• What has not improved?

• What have other people noticed?

• Is the improvement meaningful?

• Has functioning changed?

Timing

Ask:

• What time is the medication taken?

• When does benefit begin?

• When is benefit strongest?

• When does it appear to wear off?

• What happens when it wears off?

Adverse Effects

Ask about:

• appetite

• weight

• sleep

• headache

• gastrointestinal symptoms

• mood

• anxiety

• irritability

• cardiovascular symptoms

• tics or other relevant changes

Function

Ask:

• Is schoolwork improving?

• Is homework easier?

• Is work being completed?

• Are deadlines being met?

• Is family life different?

• Is the patient more independent?

• Are impulsive behaviours changing?

A good titration review should tell you much more than:

"20mg tolerated."

Use Multiple Sources of Information

For children and adolescents, information from parents and school can be particularly valuable.

A parent may report:

"He's much calmer."

The teacher may report:

"There has been no change in classroom attention."

Or the reverse may occur.

This does not necessarily mean one person is wrong.

Medication may be active during one part of the day but not another.

Environmental demands may differ.

Symptoms may also manifest differently across settings.

Collateral information can therefore help determine:

• whether treatment is working

• when it is working

• where it is working

• how long it is working

Clinical Example: "It Works, But Only Until Lunch"

A 10-year-old starts a stimulant.

His parents report improvement and school notices that he is considerably more settled during the first lessons.

However, difficulties return around lunchtime.

Do not immediately conclude:

"The dose is too low."

Ask:

Is the morning effect adequate?

If yes, increasing the dose purely to extend duration may also increase peak exposure and adverse effects.

The issue may instead be duration of action.

This might prompt consideration of formulation, timing or another clinically appropriate strategy.

Always distinguish:

insufficient intensity of effect

from

insufficient duration of effect.

They are not the same problem.

Clinical Example: "It Lasts All Day, But Doesn't Do Enough"

Now consider an adult taking a long-acting stimulant.

They report:

"I can tell it's there all day, but I'm still very distracted and I'm still not getting things finished."

Here the duration may be satisfactory.

The problem may be insufficient therapeutic effect.

That may justify cautious dose optimisation if treatment is tolerated and clinically appropriate.

Again, identify the problem before changing the prescription.

Clinical Example: "It Works Brilliantly, But I Can't Eat"

Suppose medication produces marked improvement in ADHD symptoms but appetite suppression becomes substantial.

Do not think in binary terms:

works = continue

or

side effect = stop.

Explore:

• severity

• weight trajectory

• timing

• nutritional intake

• whether appetite returns when medication wears off

• dose relationship

• formulation

• alternative treatment options

Management depends on the clinical significance of the adverse effect.

Appetite and Weight

Reduced appetite is a common concern with stimulant medication.

Ask specifically about:

• breakfast

• lunchtime intake

• evening appetite

• weight change

• food avoidance

• nutritional adequacy

Practical strategies may include ensuring good nutritional intake when stimulant effects are lower and reviewing medication timing where appropriate.

In children, monitor growth appropriately.

A mild reduction in lunchtime appetite with stable growth is different from significant or sustained weight loss.

The trajectory matters.

Sleep

Sleep problems require careful interpretation.

If sleep deteriorates after stimulant initiation, ask:

• What was sleep like before medication?

• What time is medication taken?

• When does medication wear off?

• Has the dose recently changed?

• Is evening behaviour different?

• Is caffeine being used?

• Is there significant screen use?

• Is there a pre-existing delayed sleep pattern?

• Is anxiety contributing?

Do not automatically assume:

"Stimulant equals insomnia."

Some patients actually sleep better when ADHD is effectively treated because evenings become less chaotic and mental restlessness improves.

Again, formulate before intervening.

Cardiovascular Monitoring

Stimulants can affect pulse and blood pressure.

Appropriate monitoring should therefore continue during treatment according to current clinical guidance.

Most patients will not develop serious cardiovascular complications.

However, symptoms such as:

• significant persistent palpitations

• chest pain

• syncope

• marked tachycardia

• clinically significant blood pressure changes

require appropriate assessment rather than routine continuation of titration.

Do not reassure reflexively simply because cardiovascular effects are recognised with stimulants.

Recognised adverse effects still require clinical interpretation.

Tics

Tics frequently generate concern when stimulant medication is considered.

The relationship between ADHD, tic disorders and stimulant treatment is more complicated than the simple historical message that:

"Stimulants cause tics."

ADHD and tic disorders commonly coexist.

Tics also naturally fluctuate over time.

If tics emerge or worsen during treatment, consider:

• whether the change is temporally related to medication

• whether it exceeds the person's usual fluctuation

• how impairing the tic is

• whether ADHD benefit outweighs the difficulty

• whether dose or medication adjustment is appropriate

Do not automatically assume causation simply because a tic appeared while a stimulant was being taken.

Mood, Anxiety and Behavioural Change

During titration, ask about changes in:

• irritability

• anxiety

• emotional reactivity

• mood

• agitation

• unusual behaviour

The timing can be informative.

For example:

Irritability while medication is strongly active

may suggest a different problem from:

irritability emerging consistently as medication wears off.

Do not simply record:

"Medication causes irritability."

Establish when, how severe, how consistently and in what context.

Rebound

Some patients experience a deterioration in symptoms or irritability as stimulant effects wear off.

This is sometimes described as rebound.

The important question is whether the patient is simply returning to their untreated baseline or experiencing a temporary worsening beyond baseline.

Ask:

"What were evenings like before medication?"

Then compare.

Accurate baseline information is extremely helpful.

Emotional Blunting

Occasionally patients or parents describe:

"He's not himself."

"She seems flat."

"I'm productive, but I don't feel like me."

Take this seriously.

Successful ADHD treatment should not require the individual to become emotionally blunted or lose normal spontaneity.

Consider dose, formulation and alternative treatment options.

The objective is improved regulation, not suppression of personality.

When There Is No Benefit

Suppose the patient reports no meaningful improvement.

Before declaring treatment failure, check:

Was the medication actually taken?

Adherence matters.

Was the dose adequate?

A low starting dose is not necessarily an adequate therapeutic trial.

Was the trial long and structured enough?

Consider whether titration was completed appropriately.

Were the right outcomes measured?

Perhaps the patient expected medication to improve a difficulty caused primarily by anxiety or depression.

Was the formulation appropriate?

Duration may have been mismatched to the period in which benefit was needed.

Is the diagnosis and formulation correct?

Poor response should occasionally prompt reconsideration of the wider clinical picture.

Switching Between Stimulant Classes

A patient may respond inadequately to one stimulant class despite appropriate titration.

This does not necessarily predict response to another stimulant class.

A clinically appropriate trial of the alternative stimulant class may produce a very different response.

This is why it is useful to document treatment trials clearly:

Medication

Formulation

Dose range

Duration

Benefits

Adverse effects

Reason stopped

Avoid documentation such as:

"Tried Methylphenidate – didn't work."

That provides very little information for the next clinician.

Lisdexamfetamine and Dexamfetamine

Lisdexamfetamine is a prodrug of Dexamfetamine.

This pharmacological design contributes to a different delivery profile from immediate-release Dexamfetamine.

In practice, the two should not be thought of as simply interchangeable milligram-for-milligram preparations.

If changing between stimulant preparations, use appropriate prescribing guidance rather than attempting informal dose conversions.

This principle applies more broadly:

Do not assume that equal milligram numbers mean equal clinical exposure across different stimulant products.

Do Not Chase Every Difficult Hour With Medication

Suppose a patient reports good daytime benefit but difficulties late in the evening.

Before extending medication coverage, ask:

What is happening in the evening?

Is the problem genuinely untreated ADHD?

Is the patient exhausted?

Is the evening unstructured?

Is sleep being compromised?

Would non-pharmacological strategies address the problem?

Longer medication coverage may sometimes be appropriate but not every difficult period of the day requires additional stimulant exposure.

Medication Holidays

Patients and families sometimes ask whether stimulant medication must be taken every day.

The answer should be individualised.

Consider:

• severity of impairment outside school or work

• adverse effects

• appetite and growth

• social functioning

• driving

• family functioning

• treatment goals

• the patient's preference

Avoid automatically assuming that ADHD only matters during education or employment.

A child may require regulation for friendships and family life.

An adult may require attention for driving, parenting, finances and household responsibilities.

Any planned interruption should therefore have a clinical rationale.

Adherence

Before increasing medication because:

"It isn't lasting"

or:

"It isn't working"

check how the medication is actually being taken.

Ask:

• How many doses are missed?

• Is it taken at the same time each day?

• Is it taken differently at weekends?

• Are there difficulties obtaining prescriptions?

• Is the formulation difficult to swallow?

• Is the patient deliberately avoiding it because of adverse effects?

Poor adherence can look remarkably similar to poor efficacy.

Misuse and Diversion in Practice

Approach this proportionately.

Potential warning signs might include:

• repeated unexplained losses

• frequent early requests

• inconsistent accounts of medication use

• evidence of sharing medication

• requests that raise concern about non-therapeutic use

However, avoid creating an adversarial prescribing relationship.

Most patients take their medication appropriately.

Safe prescribing involves appropriate vigilance without treating every patient as though misuse is expected.

Controlled-Drug Prescribing

Clinicians prescribing stimulants must understand the legal and professional requirements applying to the specific controlled drug being prescribed.

Practical considerations include:

• correct prescription wording

• formulation

• strength

• dose

• quantity

• duration of supply

• secure prescription processes

• arrangements for lost prescriptions

• continuity during travel

• communication between prescribers

Prescribing errors involving controlled drugs can delay treatment even when no direct clinical harm occurs.

Accuracy matters.

Shared Care

Once treatment is appropriately optimised and the patient is clinically stable, prescribing may in some circumstances be transferred under an agreed shared-care arrangement.

Shared care is not simply:

"The GP now prescribes it."

There should be clarity about:

• the medication

• formulation

• dose

• treatment response

• required monitoring

• responsibilities of primary care

• responsibilities of specialist services

• circumstances requiring specialist review

Local arrangements vary and shared care requires agreement between the relevant parties.

Do not assume that primary care is automatically required to accept prescribing responsibility.

Long-Term Review

Stimulant treatment should not become an indefinite repeat prescription without clinical review.

Long-term review should consider:

Is ADHD medication still beneficial?

Is the current dose still appropriate?

Is the duration appropriate?

Are adverse effects present?

Are physical parameters satisfactory?

Is adherence appropriate?

Has the patient's life changed?

Is the medication still needed across the same periods of the day?

Are there new psychiatric or physical health issues?

Does the overall treatment plan still make sense?

The optimal prescription at age 12 may not be the optimal prescription at age 16.

The optimal treatment during university may not be the optimal treatment once someone begins employment.

Treatment should evolve with the patient.

A Practical Titration Framework

At each titration review, think through five domains.

1. Effect

What ADHD symptoms have changed?

2. Function

What is now easier in everyday life?

3. Duration

When does benefit start and stop?

4. Tolerability

What adverse effects have emerged?

5. Safety

Are physical observations and mental state satisfactory?

Then make one of several broad decisions:

Continue current dose

Increase cautiously

Reduce

Change timing or formulation

Switch medication

Pause and investigate

Stop treatment

The decision follows the clinical information.

Clinical Case: Putting It Together

Consider a 15-year-old boy with ADHD.

His main treatment targets are:

• classroom concentration

• completing schoolwork

• reducing impulsive interruptions

• managing homework

He starts modified-release Methylphenidate.

At the first review:

• appetite is mildly reduced at lunchtime

• weight is stable

• sleep is unchanged

• pulse and blood pressure are satisfactory

• teachers report clear improvement in morning lessons

• concentration deteriorates during the afternoon

• homework remains very difficult

What should you think?

First:

Is the medication working at all?

Yes. There is clear morning benefit.

Second:

Is the problem inadequate effect or inadequate duration?

The morning response suggests that the medication is capable of producing benefit.

The timing suggests duration may be important.

Third:

Are adverse effects limiting treatment?

At present, appetite reduction is mild and weight remains stable.

Fourth:

What is the functional target?

The treatment plan includes afternoon school functioning and homework, neither of which is adequately covered.

The next decision should therefore consider the medication's duration and formulation rather than automatically concluding that Methylphenidate has failed.

This is the mindset required for stimulant prescribing.

Another Clinical Case: When Increasing Is Not the Answer

A 28-year-old woman taking a stimulant reports:

"My concentration is excellent now, but I feel tense, my heart races and I don't feel like myself."

Do not focus only on symptom improvement.

The treatment goal is not maximal concentration regardless of cost.

Ask about:

• pulse and blood pressure

• cardiovascular symptoms

• anxiety

• timing

• dose relationship

• sleep

• appetite

• emotional blunting

The appropriate response may involve reducing the dose, changing treatment or undertaking further assessment depending on the findings.

The principle is:

Benefit does not override safety and tolerability.

The Four Questions Behind Good Stimulant Prescribing

When reviewing stimulant treatment, keep returning to four questions:

Is it effective?

Are ADHD symptoms meaningfully better?

Is it functional?

Has the person's life actually improved?

Is it tolerable?

Are adverse effects acceptable?

Is it safe?

Is there any clinical reason treatment should be modified, investigated or stopped?

If all four answers are satisfactory, treatment may be appropriately optimised.

If one is not, understand why before changing the prescription.

Key Learning Points

Stimulant medication is an important evidence-based treatment for ADHD but prescribing requires structured clinical assessment and ongoing optimisation.

The principal stimulant groups are Methylphenidate-based and amphetamine-based medications.

Different formulations have different release characteristics and should not be assumed to be clinically interchangeable simply because they contain the same active ingredient or have similar milligram doses.

Before treatment, undertake an appropriate baseline assessment including physical health, cardiovascular history, relevant physical observations, mental health, current medication and misuse or diversion risk.

Define meaningful treatment targets before titration begins.

Start cautiously and explain that an initial dose may not provide full therapeutic benefit.

The objective of titration is to identify the optimal dose, not the maximum dose.

At every review assess:

effect

function

duration

tolerability

safety

Distinguish inadequate therapeutic effect from inadequate duration of action.

Monitor appetite, weight, growth where appropriate, sleep, pulse, blood pressure, mental state and other relevant adverse effects.

Take significant cardiovascular symptoms, behavioural change and other clinically important adverse effects seriously.

When response is inadequate, review adherence, dose, formulation, duration, treatment targets and the wider formulation before declaring treatment failure.

A poor response to one stimulant does not necessarily predict a poor response to another stimulant class.

Medication and non-pharmacological management are often complementary.

Controlled-drug prescribing requires accuracy and appropriate consideration of misuse, diversion and continuity of treatment.

Long-term prescribing requires ongoing clinical review rather than indefinite continuation of repeat prescriptions.

Above all, remember:

The aim of stimulant treatment is not to produce the greatest possible pharmacological effect.

It is to achieve meaningful improvement in ADHD symptoms and everyday functioning at a dose and formulation that remain safe and tolerable for the individual patient.

4. Clinical Perspective

Stimulant prescribing becomes much easier when you stop thinking primarily in terms of dose and start thinking in terms of response patterns.

At every review, the clinician should be trying to understand four things:

Is it working?

When is it working?

What happens when it is working?

What is the cost in terms of adverse effects?

The prescription should follow from those answers.

Clinical Pearls

Do Not Judge a Stimulant From the Starting Dose

One of the most common mistakes is concluding that a medication is ineffective after a low starting dose produces little benefit.

Starting doses are deliberately cautious.

A patient may report:

"I can't really tell any difference."

If the medication is well tolerated, this may simply mean that further titration is required.

Equally, do not increase automatically simply because the next dose exists on the titration schedule.

Each increase should have a clinical rationale.

The question is:

"Is there sufficient benefit to remain here, or is there a reason to cautiously optimise further?"

Separate Effect From Duration

This is one of the most useful skills in stimulant prescribing.

Suppose a parent says:

"It isn't working by 3pm."

That statement could mean two very different things.

Scenario A: The medication works extremely well between 9am and 1pm but then wears off.

That is primarily a duration problem.

Scenario B: There is little improvement at any point during the day.

That is primarily an efficacy problem.

Increasing the dose is not automatically the correct response to both situations.

Always establish the pattern across the day.

Ask What Other People Have Noticed

Patients do not always perceive their own response accurately.

A child may say:

"It doesn't do anything."

while their teacher reports substantial improvement in classroom attention and task completion.

An adult may say:

"I don't feel any different."

but then realise that they have completed their paperwork every day for the first time in years.

Medication does not necessarily need to produce a subjective sensation to be effective.

Look for observable functional change.

Establish the Baseline Before You Start

If a patient reports insomnia during titration but slept poorly before treatment, the interpretation is different from new-onset insomnia beginning immediately after a dose increase.

The same applies to:

• appetite

• anxiety

• irritability

• headaches

• tics

• palpitations

• emotional dysregulation

Good baseline assessment makes adverse-effect interpretation considerably easier.

The Best Dose Is Not the Highest Dose

If a patient has excellent symptom control at a lower dose, there is no clinical prize for reaching the maximum licensed dose.

Similarly, if increasing the dose produces slightly better concentration but substantially worse appetite, sleep or emotional wellbeing, the higher dose may not represent better treatment.

Think in terms of:

net clinical benefit.

The optimal dose is the dose at which benefit and tolerability are best balanced for that individual.

A Medication Can Work Without Being the Right Medication

A patient may obtain clear symptom improvement but experience unacceptable adverse effects.

That is still useful clinical information.

It tells you that the stimulant mechanism may be therapeutically effective but that the particular dose, formulation or medication may not provide an acceptable overall balance.

Do not equate:

"It works"

with:

"We should continue it."

Do Not Assume Milligrams Are Equivalent Across Preparations

This is particularly important with modified-release Methylphenidate.

Different preparations can have different release profiles and clinical durations.

A patient stable on one modified-release preparation may notice a meaningful difference if switched to another product even when the stated dose appears similar.

Always know exactly which preparation the patient is taking.

Practical Tips for Everyday Practice

Ask About the Whole Day

A useful stimulant review follows the patient's day chronologically.

Ask:

Morning:
What time is medication taken? When does benefit begin?

School or work:
What is different? What remains difficult?

Afternoon:
Does benefit continue? Is there a noticeable decline?

Evening:
What happens when medication wears off? How is appetite? How is family functioning?

Night:
Is sleep affected?

This often provides more clinically useful information than asking a long list of disconnected adverse-effect questions.

Ask for Examples Rather Than Ratings Alone

Instead of:

"Is concentration better?"

ask:

"What can you do now that was difficult before?"

You may hear:

"I can sit through a meeting without losing the conversation."

"I completed three lessons without leaving my seat."

"I can actually finish my documentation before going home."

These examples tell you whether medication is producing meaningful benefit.

Clarify What "Wearing Off" Means

Patients use this phrase differently.

Ask:

"What actually happens when you say it wears off?"

They may describe:

• return of distractibility

• increased impulsivity

• restlessness

• hunger

• fatigue

• irritability

• headache

• emotional deterioration

This distinction may influence management.

Check Adherence Before Changing Medication

Before increasing the dose or switching treatment, ask:

"How often are you actually taking it?"

Also ask:

"What time do you take it?"

A medication cannot be meaningfully evaluated if it is being taken inconsistently.

Explore why doses are missed rather than simply documenting non-adherence.

Ask About Food Properly

Do not simply ask:

"Is appetite okay?"

Ask:

"What are you eating for breakfast?"

"What happens at lunchtime?"

"When does your appetite return?"

"Are you eating normally in the evening?"

This gives a much better picture of nutritional impact.

For children and young people, examine the growth trajectory rather than focusing on a single weight measurement.

Ask About Sleep Before Prescribing for Sleep

If sleep deteriorates, establish:

• medication timing

• duration of stimulant effect

• baseline sleep pattern

• bedtime routine

• caffeine

• screen use

• anxiety

• evening rebound

• whether the patient is actually tired at bedtime

The solution should follow the mechanism.

Document Medication Trials Properly

For every significant medication trial, record:

Medication and formulation

Dose range

Clinical benefit

Duration of benefit

Adverse effects

Reason for changing or stopping

This becomes extremely valuable later.

Avoid:

"Previously tried Ritalin – ineffective."

That does not tell the next clinician whether the patient received an adequate trial.

Common Pitfalls and Misconceptions

"No Benefit at the Starting Dose Means Treatment Failure"

Usually not.

A starting dose is often intended primarily to establish tolerability before further titration.

The adequacy of the overall trial matters.

"If It Wears Off Early, Increase the Dose"

Not necessarily.

Increasing a dose may increase intensity of effect without adequately solving the duration problem.

First determine whether the medication works well while active.

"If Symptoms Remain, Keep Increasing"

Not necessarily.

Persistent difficulties may reflect:

• inadequate dose

• inadequate duration

• poor adherence

• unsuitable formulation

• environmental demands

• comorbidity

• unrealistic treatment expectations

• difficulties that medication is not expected to resolve

Reformulate before escalating indefinitely.

"The Patient Should Feel the Medication Working"

Not necessarily.

Some patients describe a noticeable subjective change.

Others simply notice that life becomes easier.

Functional improvement is more important than whether the medication produces an obvious internal sensation.

"Stimulants Should Change Personality"

They should not.

A parent may understandably appreciate reduced hyperactivity but treatment should not aim to make a lively child unusually quiet.

If someone becomes markedly flat, withdrawn or unlike themselves, review the treatment.

The aim is better regulation, not suppression of normal personality.

"Every Palpitation Is Benign Because Stimulants Increase Heart Rate"

Do not make this assumption.

Mild changes in pulse can occur but clinically significant cardiovascular symptoms require appropriate assessment.

Chest pain, syncope, significant persistent palpitations or marked cardiovascular abnormalities should not simply be attributed to an expected stimulant effect.

"Every New Tic Was Caused by the Stimulant"

Not necessarily.

Tic disorders and ADHD commonly coexist and tics naturally fluctuate.

Consider timing, previous history, severity and the relationship to dose before determining causation.

"A Child Only Needs Medication for School"

ADHD does not stop when school finishes.

Consider:

• homework

• friendships

• family relationships

• activities

• impulsive behaviour

• independence

• evening functioning

Treatment duration should reflect the individual's functional needs.

"Adults Only Need Medication for Work"

Similarly, adults may require effective attention and impulse control for:

• driving

• parenting

• relationships

• finances

• household responsibilities

• education

• social functioning

Treatment goals should encompass the person's life rather than their productivity alone.

Advice for Newly Qualified Doctors

Never Increase a Dose Without Knowing Why

Before changing the prescription, complete the sentence:

"I am increasing this medication because..."

A good answer might be:

"There is partial improvement in attention and impulsivity, adverse effects remain minimal and significant target symptoms persist throughout the period when medication is active."

A poor answer is:

"Because that is the next dose."

Learn the Formulations You Prescribe

Do not attempt to memorise every ADHD medication immediately.

Start by becoming very familiar with the preparations you commonly prescribe.

Know:

• whether they are immediate or modified release

• approximate expected duration

• relevant administration instructions

• available strengths

• important formulation differences

This prevents many avoidable prescribing errors.

Do Not Prescribe From the Previous Clinic Letter Alone

Confirm what the patient is actually taking.

Medication lists can become inaccurate.

Ask:

"What medication are you currently taking?"

"What strength?"

"How many?"

"What time?"

This is particularly important when prescriptions have changed during titration.

Take Physical Observations Seriously

Pulse, blood pressure, weight and growth monitoring are not administrative obstacles to prescribing.

They are part of safe treatment.

If observations are abnormal, interpret them clinically rather than simply copying them into the record and continuing.

Know When to Stop Titrating

Sometimes the safest decision is:

do not increase today.

This may be appropriate because:

• physical observations require review

• significant adverse effects have emerged

• cardiovascular symptoms require assessment

• the mental state has changed

• the history is unclear

• adherence is uncertain

• the current response has not been adequately assessed

You do not need to complete a titration schedule simply because one was originally planned.

Ask for Senior Advice Early

Newly qualified doctors sometimes worry that asking for advice suggests a lack of competence.

Stimulant prescribing involves clinical judgement.

Seek senior input when:

• cardiovascular concerns arise

• significant psychiatric deterioration occurs

• there is diagnostic uncertainty

• adverse effects are difficult to interpret

• complex comorbidity is present

• misuse or diversion is suspected

• prescribing falls outside familiar practice

• you are uncertain whether treatment should continue

Knowing when to seek advice is part of safe prescribing.

Situations Requiring Particular Clinical Judgement

Chest Pain or Significant Palpitations

Do not simply reduce the dose by telephone and continue titration without understanding what happened.

Establish:

• nature of symptoms

• timing

• severity

• associated breathlessness

• dizziness

• syncope

• relationship to exertion

• current cardiovascular observations where appropriate

• relevant cardiac history

Depending on the presentation, stimulant treatment may need to be withheld while appropriate medical assessment takes place.

Clinical urgency should reflect the symptoms and wider presentation.

Emerging Mania or Psychosis

A significant change in mental state during stimulant treatment requires careful assessment.

Symptoms suggestive of mania or psychosis should not be managed simply by adjusting the titration schedule.

Consider the temporal relationship with medication and undertake an appropriate psychiatric assessment.

Patient safety takes priority over completing ADHD titration.

Significant Anxiety

Anxiety and ADHD frequently coexist.

Stimulants do not inevitably worsen anxiety and effective ADHD treatment may improve anxiety for some individuals by reducing functional chaos.

However, if anxiety clearly deteriorates during titration, consider:

• dose

• timing

• physical stimulant effects

• baseline anxiety

• other medication

• caffeine

• the wider formulation

Avoid simplistic rules such as:

"ADHD plus anxiety means stimulants should not be used."

Autism and ADHD

Autistic individuals frequently have co-occurring ADHD and may benefit from stimulant treatment.

However, individual tolerability can vary.

Use careful titration and monitor:

• appetite

• sleep

• irritability

• emotional or behavioural change

• functional benefit

Do not deny evidence-based ADHD treatment simply because autism is also present.

Substance Misuse

This requires individualised assessment.

Consider:

• current substances

• severity

• pattern of use

• motivation

• risk of diversion

• formulation

• treatment setting

• safeguarding

• wider psychiatric risk

Neither extreme is appropriate:

"Anyone with substance misuse should never receive stimulants."

or

"The substance misuse is irrelevant because ADHD has been diagnosed."

Clinical judgement is required.

Significant Weight Loss

Do not simply advise:

"Eat more."

Assess:

• trajectory

• amount of weight lost

• nutritional intake

• appetite pattern

• dose relationship

• formulation

• other causes of weight loss

The response may include nutritional strategies, dose or timing changes, treatment modification or further medical assessment depending on severity.

Poor Response to Both Stimulant Classes

At this stage, reconsider the whole picture.

Ask:

Was the diagnosis secure?

Were adequate treatment trials undertaken?

Was adherence sufficient?

Were the correct outcomes assessed?

Is another condition driving the impairment?

Are environmental factors overwhelming the treatment effect?

Would non-stimulant treatment be more appropriate?

Poor medication response is sometimes a treatment problem.

Occasionally it is a signal to revisit the formulation.

Requests for Rapid Dose Escalation

Some patients understandably want to reach an effective dose quickly.

Explain that titration exists to establish both benefit and tolerability.

Do not accelerate treatment beyond safe prescribing practice simply because the patient reports little effect from the starting dose.

Conversely, do not leave patients for unnecessarily prolonged periods on clearly subtherapeutic doses without clinical reason.

Safe titration should be cautious but purposeful.

Repeated Lost Medication or Early Prescription Requests

Do not automatically accuse the patient of misuse.

There may be legitimate explanations.

However, repeated patterns require exploration because stimulant medication has diversion and misuse potential.

Document concerns clearly and consider whether prescribing arrangements need modification.

A Useful Review Framework

At every stimulant review, consider:

1. What has improved?

Look for symptoms and functioning.

2. What remains difficult?

Identify residual treatment targets.

3. When does the medication work?

Establish onset and duration.

4. What adverse effects are occurring?

Assess severity and clinical significance.

5. Are physical observations satisfactory?

Review relevant monitoring.

6. Is the medication being taken as intended?

Check adherence and administration.

7. What should change?

Decide whether to:

continue

increase

reduce

modify formulation or timing

switch treatment

pause and investigate

or

stop

Every prescribing decision should be traceable back to the clinical information.

Final Clinical Message

The most important skill in stimulant prescribing is not memorising dose schedules.

It is learning how to interpret patterns of response.

When medication appears ineffective, determine whether the problem is efficacy, dose, duration, adherence, formulation or formulation of the underlying difficulty.

When adverse effects occur, determine their severity, timing and clinical significance.

When treatment appears successful, confirm that the improvement is translating into meaningful everyday functioning.

Do not chase the maximum dose.

Do not dismiss a medication because the starting dose produced little benefit.

Do not increase a medication simply because symptoms return after it has worn off.

Do not ignore significant adverse effects because the medication is effective.

At every stage ask:

Is it effective?

Is it improving functioning?

Is it tolerable?

Is it safe?

The best stimulant prescription is not the strongest one.

It is the lowest appropriate dose and formulation that provides sufficient clinically meaningful benefit with acceptable adverse effects and appropriate safety monitoring.

5. Summary

Stimulant medication is an important evidence-based treatment for ADHD, but safe and effective prescribing requires considerably more than selecting a drug and increasing the dose. Good prescribing is a structured process of selection, initiation, titration, monitoring and review.

The two principal stimulant groups used in ADHD treatment are Methylphenidate-based medications and amphetamine-based medications, including Lisdexamfetamine and Dexamfetamine. Individuals may respond differently to each group, so an inadequate response to one stimulant does not necessarily mean that stimulant treatment as a whole has failed.

Medication choice should be individualised. Clinicians should consider age, required duration of effect, daily routine, previous response, comorbidity, adherence, ability to take the formulation, patient preference and the potential for misuse or diversion.

Immediate-release and modified-release preparations have different practical advantages and disadvantages. Modified-release Methylphenidate products can also differ in their release profiles and should not automatically be considered clinically interchangeable simply because they contain the same active ingredient or have the same stated dose.

Before treatment begins, an appropriate baseline assessment is required. This should include relevant physical and psychiatric history, current medication, cardiovascular assessment, pulse, blood pressure, weight and height where appropriate, as well as consideration of substance misuse and diversion risk.

Titration should be cautious but purposeful. Starting doses may provide limited therapeutic benefit because they are intended partly to establish tolerability before further optimisation. A lack of benefit at the starting dose should therefore not automatically be interpreted as treatment failure.

The aim of titration is not to reach the highest available dose. It is to identify the dose and formulation that provide the best balance between:

symptom improvement

functional benefit

duration of action

tolerability

and

safety

At every review, clinicians should consider what has improved, what remains difficult, when the medication starts to work, how long the benefit lasts and what adverse effects have emerged.

A particularly important skill is distinguishing insufficient effect from insufficient duration of effect. If medication works well while active but wears off too early, the problem may relate to formulation or duration rather than dose. If the medication lasts throughout the required period but produces little improvement, cautious dose optimisation or a change in treatment may be more appropriate.

Medication effectiveness should be judged through meaningful functional outcomes as well as symptom reports. Examples include improved classroom engagement, better task completion, fewer missed deadlines, reduced impulsive behaviour and improved everyday organisation.

Adverse effects require clinical interpretation rather than automatic continuation or discontinuation. Appetite suppression, sleep difficulties, headaches, gastrointestinal symptoms, cardiovascular changes, irritability, anxiety, tics and emotional blunting should be assessed according to severity, timing, persistence, dose relationship and impact on functioning.

Appetite and weight monitoring are particularly important. In children and young people, the trajectory of growth matters more than a single isolated measurement. Significant or sustained weight loss requires active clinical review rather than simple reassurance.

Sleep difficulties should also be carefully formulated. Not all sleep problems during stimulant treatment are necessarily caused by medication. Baseline sleep, medication timing, evening rebound, caffeine, screen use, anxiety and pre-existing sleep disorders may all contribute.

Clinically significant cardiovascular symptoms such as chest pain, syncope, marked tachycardia or significant persistent palpitations require appropriate assessment and should not simply be attributed to expected stimulant effects.

Tics may coexist with ADHD and can fluctuate naturally over time. If tics emerge or worsen during treatment, clinicians should consider timing, baseline history, severity and the relationship to medication before assuming causation.

Mental state should remain under review throughout treatment. Emerging mania, psychosis or significant behavioural or emotional deterioration requires careful assessment and may take priority over continuation of the ADHD titration pathway.

When medication appears ineffective, review adherence, administration, formulation, dose, duration, treatment targets and the broader diagnostic formulation before concluding that treatment has failed.

Medication trials should be documented clearly, including the formulation, dose range, benefits, duration of effect, adverse effects and reason for stopping or changing treatment. Statements such as "Methylphenidate did not work" provide insufficient information for future clinical decision-making.

Stimulant prescribing also requires awareness of controlled-drug responsibilities, safe prescribing processes, misuse and diversion risk and continuity of treatment.

Long-term stimulant treatment should not become an indefinite repeat prescription without review. Clinicians should periodically reconsider whether the medication remains beneficial, appropriately dosed, well tolerated and suited to the patient's current circumstances.

Medication and non-pharmacological management are often complementary. Stimulant treatment may improve attention and impulse control, but it does not automatically create organisational systems, resolve longstanding behavioural patterns or address every environmental or psychological difficulty.

The practical framework for every stimulant review can therefore be summarised as:

Is it effective?

Is it improving functioning?

Is the duration appropriate?

Is it tolerable?

Is it safe?

The best stimulant treatment is not the highest dose or the longest-acting formulation.

It is the lowest appropriate dose and formulation that provides sufficient clinically meaningful benefit with acceptable adverse effects and appropriate safety monitoring.

6. Further Reading

The following resources provide a strong evidence base for understanding the use of stimulant medication in ADHD. Clinicians should combine evidence from guidelines and research with current prescribing information, local policies and individual clinical assessment.

Relevant NICE Guidance

National Institute for Health and Care Excellence (NICE)

Attention Deficit Hyperactivity Disorder: Diagnosis and Management (NG87)

This is the principal UK clinical guideline for ADHD and should be the starting point for clinicians practising in the UK.

NICE provides recommendations covering:

• when medication should be considered

• baseline assessment before medication

• medication choice

• Methylphenidate

• Lisdexamfetamine and Dexamfetamine

• medication titration

• cardiovascular assessment

• monitoring of pulse and blood pressure

• monitoring of height and weight

• management of adverse effects

• adherence

• medication review

• planned discontinuation or dose reduction

• considerations relating to misuse and diversion

For children aged 5 years and over and young people, NICE recommends Methylphenidate as first-line pharmacological treatment. If an adequate trial at an adequate dose has not produced sufficient benefit, Lisdexamfetamine can be considered.

For adults, NICE recommends Lisdexamfetamine or Methylphenidate as first-line pharmacological treatment.

NICE NG87: Attention deficit hyperactivity disorder – diagnosis and management

Particularly Important NICE Sections

Doctors prescribing stimulant medication should become familiar with the sections covering:

Medication choice

Baseline assessment

Dose titration

Maintenance and monitoring

Cardiovascular monitoring

Height and weight monitoring

Sleep

Tics

Adherence

Medication review and discontinuation

These sections are particularly useful because they translate the evidence into practical prescribing recommendations.

International Clinical Guidelines

Australian Evidence-Based Clinical Practice Guideline for ADHD

Australian ADHD Professionals Association (AADPA).

Australian Evidence-Based Clinical Practice Guideline for Attention Deficit Hyperactivity Disorder.

This provides an extensive evidence-based discussion of pharmacological ADHD treatment across the lifespan.

The guideline recommends stimulants as first-line medication for children aged 6 years and over, adolescents and adults unless they cannot take them because of other health problems. It also emphasises individual dose optimisation and recommends trialling the alternative stimulant when the first stimulant produces inadequate benefit or problematic adverse effects.

Particularly useful sections include:

• starting pharmacological treatment

• medication choice

• titration

• monitoring

• adherence

• medication review

• discontinuation

The guideline is particularly valuable alongside NICE because it provides extensive discussion of the evidence underlying individual recommendations.

Australian Evidence-Based Clinical Practice Guideline for ADHD

Canadian ADHD Practice Guidelines

Canadian ADHD Resource Alliance (CADDRA).

Canadian ADHD Practice Guidelines, 4.1 Edition.

The CADDRA guidelines provide a highly practical approach to ADHD assessment and pharmacological treatment across the lifespan.

They divide psychostimulants into the two principal groups:

amphetamine-based stimulants

and

Methylphenidate-based stimulants.

A particularly useful clinical principle emphasised by CADDRA is that response to one stimulant class does not reliably predict response to the other. Consequently, an inadequate response to one class should not automatically be interpreted as failure of stimulant treatment generally.

The guidelines are also useful for understanding differences between short-acting and long-acting preparations, practical medication selection and ongoing monitoring.

CADDRA Canadian ADHD Practice Guidelines

Landmark Research

The Multimodal Treatment Study of Children with ADHD – MTA Study

The MTA Cooperative Group.

A 14-Month Randomized Clinical Trial of Treatment Strategies for Attention-Deficit/Hyperactivity Disorder.Archives of General Psychiatry. 1999;56(12):1073–1086.

The MTA study is one of the landmark trials in ADHD treatment research.

It included 579 children with ADHD who were allocated to:

• carefully managed medication treatment

• intensive behavioural treatment

• combined medication and behavioural treatment

• routine community care

At 14 months, carefully managed medication and combined treatment produced greater improvement in core ADHD symptoms than behavioural treatment alone or routine community care. Combined treatment also demonstrated advantages in some broader outcomes.

The study remains particularly important for understanding the value of systematic medication management rather than simply whether medication was prescribed.

MTA Cooperative Group – 14-month randomised clinical trial

Comparative Medication Effectiveness

Cortese et al. – Network Meta-analysis

Cortese S, Adamo N, Del Giovane C, et al.

Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis.The Lancet Psychiatry. 2018;5(9):727–738.

This is an important systematic review and network meta-analysis comparing commonly used ADHD medications.

The analysis included 133 double-blind randomised controlled trials involving more than 14,000 children and adolescents and more than 10,000 adults.

For short-term treatment, the analysis supported Methylphenidate as the preferred first-choice medication in children and adolescents when efficacy and tolerability were considered together while amphetamines were supported in adults. The authors also highlighted the relative lack of robust longer-term randomised evidence.

This paper is particularly useful for understanding an important distinction:

The medication with the greatest average efficacy is not necessarily the medication with the best overall balance of efficacy and tolerability for a particular age group or individual patient.

Cortese et al. – comparative efficacy and tolerability of ADHD medications

Comparing Stimulant Classes

Faraone and Buitelaar

Faraone SV and Buitelaar J.

Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis.European Child & Adolescent Psychiatry. 2010;19(4):353–364.

This meta-analysis examined the efficacy of stimulant medications in children and adolescents.

It is useful for understanding the evidence surrounding differences between Methylphenidate and amphetamine-based stimulants while also highlighting the limitations inherent in comparing medications when relatively few direct head-to-head trials are available.

Faraone and Buitelaar – comparing stimulant efficacy

A Useful Review of the MTA Findings

Murray et al.

Murray DW, Arnold LE, Swanson J, et al.

A Clinical Review of Outcomes of the Multimodal Treatment Study of Children with Attention-Deficit/Hyperactivity Disorder (MTA).Current Psychiatry Reports. 2008;10(5):424–431.

This review is useful after reading the original MTA study because it considers the broader findings and their clinical interpretation.

It discusses:

• medication and behavioural treatment

• longer-term outcomes

• treatment moderators

• substance-use outcomes

• growth

• implications for clinical practice

It also illustrates why long-term ADHD treatment evidence needs to be interpreted more cautiously than the relatively strong evidence for short-term stimulant efficacy.

Murray et al. – clinical review of the MTA study

What Clinicians Should Take From the Evidence

The literature supports several important principles for clinical practice.

Stimulants are effective treatments for core ADHD symptoms

Randomised trials and meta-analyses consistently demonstrate clinically meaningful short-term improvements in ADHD symptoms with stimulant medication.

Response is individual

Population-level evidence tells us which medications tend to work well across groups of patients.

It does not tell us which stimulant will be optimal for the person sitting in front of us.

A patient may respond substantially better to one stimulant class than another.

Optimisation matters

Medication should be titrated according to benefit and adverse effects rather than according to a predetermined aim of reaching a particular dose. Both NICE and international guidance emphasise individual optimisation.

Medication management involves more than symptom reduction

Clinicians should consider whether improvements in core symptoms translate into meaningful changes in functioning.

This is why treatment targets should be identified before titration begins.

Short-term evidence is stronger than long-term randomised evidence

The evidence supporting short-term stimulant efficacy is substantial. The long-term evidence base is more difficult to interpret and extended randomised controlled data are comparatively limited. The Cortese network meta-analysis found insufficient data for its planned 26-week and 52-week analyses.

This should encourage appropriate long-term review rather than the assumption that a prescription that was appropriate several years ago necessarily remains optimal today.

Recommended Reading Priorities

For doctors with limited time, I would suggest the following order:

1. NICE NG87 – ADHD: Diagnosis and Management

Essential for UK clinical practice. Focus particularly on medication choice, baseline assessment, titration and monitoring.

2. Australian Evidence-Based Clinical Practice Guideline for ADHD – Pharmacological Interventions

An excellent detailed companion to NICE covering medication initiation, choice, monitoring, adherence and discontinuation.

3. CADDRA Canadian ADHD Practice Guidelines

Particularly useful for practical prescribing and understanding stimulant formulations and the clinical implications of the two stimulant classes.

4. Cortese et al. (2018)

Essential for understanding the comparative short-term efficacy and tolerability of ADHD medications across age groups.

5. MTA Cooperative Group (1999)

A landmark study for understanding systematic medication management and multimodal ADHD treatment in childhood.

6. Faraone and Buitelaar (2010)

Useful additional reading on the comparative efficacy of stimulant classes in children and adolescents.

Final Reading Message

The evidence base supports stimulant medication as an important and effective treatment for ADHD.

However, evidence-based prescribing does not mean selecting whichever drug has the largest average effect size.

Guidelines and clinical trials need to be translated into individual prescribing decisions.

For every patient, the clinician still needs to determine:

Which medication is appropriate?

Which formulation fits the patient's needs?

What dose provides sufficient benefit?

How long does the benefit last?

What adverse effects occur?

Is functioning meaningfully better?

Is treatment safe?

Does the overall balance of benefits and harms justify continuing treatment?

Guidelines provide the framework.

Clinical trials provide the evidence.

Careful individual titration and monitoring turn that evidence into good clinical practice.

7. Knowledge Check

The following questions are designed to reinforce the practical principles of safe and effective stimulant prescribing. For each question, select the single best answer.

Question 1

A 12-year-old boy with ADHD starts a low dose of modified-release Methylphenidate. After one week, his parents report no clear improvement in attention or impulsivity. He has experienced no significant adverse effects and his physical observations remain satisfactory.

What is the most appropriate interpretation?

A. Methylphenidate has failed and should immediately be stopped.

B. The absence of benefit proves that stimulant medication will not work for him.

C. The starting dose may not yet provide sufficient therapeutic benefit and further cautious titration may be appropriate.

D. The dose should immediately be increased to the maximum licensed dose.

Correct Answer: C

Explanation

A. Incorrect. A low starting dose does not necessarily constitute an adequate therapeutic trial. Starting doses are often deliberately cautious to assess tolerability before further optimisation.

B. Incorrect. Lack of response to an initial dose does not demonstrate that the patient will not respond to an adequately titrated stimulant.

C. Correct. If the medication is tolerated, observations remain satisfactory and clinically significant target symptoms persist, further cautious titration may be appropriate. The aim is to identify the dose providing the best balance between benefit and adverse effects.

D. Incorrect. Titration should be gradual and clinically guided. The objective is not to reach the maximum dose as quickly as possible.

Question 2

A 10-year-old girl taking modified-release Methylphenidate shows substantial improvement in attention and classroom behaviour between 9am and 1pm. Her ADHD symptoms then return during the afternoon.

What is the most important issue to consider?

A. The medication is completely ineffective.

B. The duration of therapeutic effect may be insufficient.

C. The ADHD diagnosis is probably incorrect.

D. The medication should automatically be stopped.

Correct Answer: B

Explanation

A. Incorrect. There is clear evidence of therapeutic benefit during the morning.

B. Correct. The pattern suggests that the medication works while active but does not provide sufficient duration of symptom control. Formulation, timing and other appropriate treatment options should therefore be considered.

C. Incorrect. A clear period of improvement provides no reason in itself to question the diagnosis.

D. Incorrect. The medication is producing meaningful benefit. The task is to optimise treatment rather than automatically discontinue it.

The key clinical distinction is:

Insufficient effect ≠ insufficient duration.

Question 3

A 32-year-old man taking a stimulant says:

"I don't feel the medication doing anything."

However, since starting treatment he has stopped missing work deadlines, completes his administrative tasks consistently and his partner reports that he interrupts conversations considerably less frequently.

What is the best interpretation?

A. The medication is ineffective because he cannot subjectively feel it working.

B. The medication appears to be producing meaningful functional benefit.

C. The dose should be increased until he can clearly feel the stimulant effect.

D. Functional improvement is less important than subjective awareness of medication.

Correct Answer: B

Explanation

A. Incorrect. Patients do not necessarily experience an obvious subjective sensation when stimulant medication is effective.

B. Correct. Improvements in deadlines, task completion and conversational impulsivity represent clinically meaningful functional changes.

C. Incorrect. The aim is not to produce a noticeable stimulant sensation. Increasing an already effective dose unnecessarily may increase adverse effects.

D. Incorrect. Functional improvement is a central measure of treatment effectiveness.

Medication should improve the patient's life rather than simply make them feel medicated.

Question 4

A child taking stimulant medication has excellent improvement in ADHD symptoms following a dose increase. However, his parents report that he has become unusually quiet, emotionally flat and "not himself".

What is the most appropriate response?

A. Continue unchanged because ADHD symptoms have improved.

B. Increase the dose further because reduced activity demonstrates effectiveness.

C. Review the dose and treatment because emotional blunting may indicate that the current regimen is not optimal.

D. Explain that personality change is an expected goal of stimulant treatment.

Correct Answer: C

Explanation

A. Incorrect. Symptom improvement does not justify ignoring clinically significant adverse effects.

B. Incorrect. Reduced activity should not be confused with optimal ADHD treatment.

C. Correct. Effective treatment should improve regulation without suppressing normal personality or emotional responsiveness. The dose, formulation and overall treatment should be reviewed.

D. Incorrect. Personality change is not the therapeutic objective.

The goal is:

better regulation, not behavioural suppression.

Question 5

A 16-year-old taking a stimulant develops chest pain and significant palpitations three days after a dose increase.

What is the most appropriate approach?

A. Reassure the family that stimulants commonly increase heart rate and continue treatment without further assessment.

B. Increase the dose to determine whether the symptoms persist.

C. Assess the symptoms appropriately and consider withholding stimulant treatment while clinically significant cardiovascular symptoms are investigated.

D. Assume the symptoms are anxiety because the patient is young.

Correct Answer: C

Explanation

A. Incorrect. Although stimulants can affect pulse and blood pressure, significant cardiovascular symptoms should not automatically be considered benign.

B. Incorrect. Increasing medication in the presence of concerning cardiovascular symptoms would be inappropriate.

C. Correct. The nature and severity of the chest pain and palpitations should be assessed alongside associated symptoms, cardiovascular observations and relevant history. Depending on the presentation, medication may need to be withheld pending appropriate medical assessment.

D. Incorrect. Anxiety may cause similar symptoms but should not be assumed without assessment.

A recognised medication adverse effect still requires clinical interpretation.

Question 6

A patient taking a long-acting stimulant reports excellent symptom control throughout the working day but develops substantial appetite suppression and clinically significant weight loss.

Which statement is most accurate?

A. The medication must be continued because it is effective.

B. Weight loss is expected with stimulants and therefore does not require review.

C. The treatment needs review because effectiveness must be balanced against tolerability and physical health.

D. The dose should be increased to compensate for the weight loss.

Correct Answer: C

Explanation

A. Incorrect. Therapeutic effectiveness does not override clinically significant adverse effects.

B. Incorrect. Reduced appetite can occur with stimulant treatment but clinically significant or sustained weight loss requires active assessment.

C. Correct. Review should consider the weight trajectory, nutritional intake, appetite pattern, dose, formulation and other possible causes. Management may involve nutritional strategies, treatment modification or further assessment depending on severity.

D. Incorrect. Increasing the dose could worsen appetite suppression.

The relevant concept is net clinical benefit, not efficacy alone.

Question 7

An adult has received an adequate trial of one stimulant class with careful titration but obtains little meaningful benefit despite satisfactory adherence. What is the most appropriate general principle?

A. Failure of one stimulant proves that all stimulant treatment will be ineffective.

B. A clinically appropriate trial of the alternative stimulant class may still produce benefit.

C. Continue increasing the first stimulant indefinitely.

D. The ADHD diagnosis must automatically be withdrawn.

Correct Answer: B

Explanation

A. Incorrect. Individual responses to Methylphenidate-based and amphetamine-based stimulants vary.

B. Correct. Inadequate response to one stimulant class does not reliably predict inadequate response to the other. An appropriately supervised trial of the alternative class may therefore be considered according to current guidance and the individual clinical circumstances.

C. Incorrect. Dose escalation should stop when further increases are inappropriate, ineffective or poorly tolerated.

D. Incorrect. Medication response is not itself a diagnostic test for ADHD.

However, repeated poor treatment response should prompt the clinician to reconsider adherence, adequacy of previous trials, treatment targets and the wider formulation.

Question 8

A patient has been stable on one brand of modified-release Methylphenidate. The clinician is considering changing to another modified-release Methylphenidate product at the same stated milligram dose.

Which statement is most accurate?

A. All modified-release Methylphenidate preparations are clinically identical.

B. Equal milligram doses guarantee identical onset and duration.

C. Different preparations can have different release characteristics, so switching products may alter the clinical effect.

D. Brand and formulation are irrelevant provided that the active ingredient is Methylphenidate.

Correct Answer: C

Explanation

A. Incorrect. Modified-release preparations are not necessarily equivalent in their release characteristics.

B. Incorrect. The same total milligram dose does not guarantee the same pattern of drug delivery or clinical effect.

C. Correct. Different products may release different proportions of Methylphenidate at different stages of the day. This can influence onset, peak effect and duration.

D. Incorrect. Formulation can be clinically important. This is one reason clinicians should know precisely which preparation their patient is taking.

Do not think only:

"Methylphenidate 20mg."

Ask:

"Which Methylphenidate 20mg preparation?"

Question 9

An 11-year-old with ADHD starts stimulant medication. Two weeks later his parents report increased irritability every evening at approximately 5pm. During the school day he is functioning considerably better.

What should the clinician do first?

A. Diagnose a new mood disorder.

B. Immediately increase the morning stimulant dose.

C. Establish the timing of medication effect and determine whether the irritability occurs as treatment is wearing off.

D. Assume that the parents are misinterpreting normal behaviour.

Correct Answer: C

Explanation

A. Incorrect. A new mood disorder should not be diagnosed solely from a time-linked period of evening irritability.

B. Incorrect. Increasing the dose without understanding the response pattern may worsen adverse effects and does not necessarily address the underlying problem.

C. Correct. Timing provides important diagnostic information. The clinician should determine when medication is taken, when benefit begins, when it ends and whether irritability represents rebound, return to baseline behaviour or another problem.

D. Incorrect. The report should be explored rather than dismissed.

When evaluating adverse effects, always ask:

When does it happen?

Question 10

A 14-year-old is doing extremely well on stimulant medication during school hours. His parents ask whether he should automatically stop taking medication every weekend because he does not attend school.

What is the best response?

A. Yes. ADHD medication is only required for academic functioning.

B. Yes. All children taking stimulants should have routine weekend medication holidays.

C. The decision should be individualised according to impairment, adverse effects, treatment goals and functioning outside school.

D. No. Once stimulant medication has been started, treatment should never be interrupted.

Correct Answer: C

Explanation

A. Incorrect. ADHD can affect much more than academic performance. Symptoms may influence family relationships, friendships, activities, independence and safety.

B. Incorrect. Planned treatment interruptions may sometimes be clinically appropriate but should not be applied automatically to every patient.

C. Correct. The clinician should consider the child's functioning across the whole week, treatment benefits, adverse effects and the reasons for considering an interruption. Any planned break should have a clear clinical rationale.

D. Incorrect. Stimulant treatment does not necessarily have to continue every day indefinitely. Treatment should be reviewed and individualised.

ADHD exists outside the classroom.

Knowledge Check Summary

These questions illustrate the central principles of safe stimulant prescribing.

A low starting dose with limited benefit does not necessarily represent treatment failure. Titration should be cautious but purposeful and should continue where clinically appropriate until an optimal balance between benefit and tolerability has been identified.

Always distinguish between:

insufficient therapeutic effect

and

insufficient duration of therapeutic effect.

They may require different solutions.

Treatment effectiveness should be judged through functional improvement as well as changes in symptoms. Patients do not necessarily need to feel medication working for treatment to be effective.

The best dose is not the highest dose. Increasing medication should always have a clinical rationale.

Adverse effects must be considered alongside benefit. Significant appetite or weight changes, emotional blunting, cardiovascular symptoms, sleep disturbance, mood changes and other clinically important problems require appropriate assessment.

A medication can improve ADHD symptoms and still be the wrong dose, formulation or treatment for the individual if the adverse effects are unacceptable.

Response to one stimulant class does not necessarily predict response to another. An adequate trial of the alternative stimulant class may therefore be appropriate when the first has produced insufficient benefit or unacceptable adverse effects.

Modified-release stimulant preparations are not necessarily interchangeable. Clinicians should understand the formulation they prescribe rather than considering only the active ingredient and total milligram dose.

Medication should be considered across the patient's whole life, not simply during school or working hours.

Finally, every stimulant review should return to five questions:

Is it effective?

Is it improving functioning?

Is the duration appropriate?

Is it tolerable?

Is it safe?

Those questions provide the foundation for rational stimulant titration and long-term ADHD prescribing.